9 results on '"Echavarría Íñiguez, Ana"'
Search Results
2. RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine.
- Author
-
Romero del Rincón, Celia, Gonzalez‐Martinez, Alicia, Quintas, Sonia, García‐Azorín, David, Fernández Lázaro, Iris, Guerrero‐Peral, Angel Luis, Gonzalez Osorio, Yesica, Santos‐Lasaosa, Sonia, González Oria, Carmen, Sánchez Rodríguez, Norberto, Iglesias Díez, Fernando, Echavarría Íñiguez, Ana, Gil Luque, Sendoa, Huerta‐Villanueva, Mariano, Campoy Díaz, Sergio, Muñoz‐Vendrell, Albert, Lozano Ros, Alberto, Sánchez‐Soblechero, Antonio, Velasco Juanes, Fernando, and Kortazar‐Zubizarreta, Izaro
- Subjects
PEPTIDES ,CALCITONIN gene-related peptide ,MIGRAINE ,TERMINATION of treatment ,MONOCLONAL antibodies - Abstract
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti‐CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti‐CGRP MAb (T‐baseline); last month of first treatment period (T‐suspension); month of restart due to worsening (T‐worsening); and 3 months after resumption (T‐reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T‐baseline was 20 (13) and MMD was 5 (6); at T‐suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T‐worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T‐reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti‐CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.
- Author
-
Gonzalez-Martinez, Alicia, Sanz-García, Ancor, García-Azorín, David, Rodríguez-Vico, Jaime, Jaimes, Alex, García, Andrea Gómez, Casas-Limón, Javier, Terán, Javier Díaz de, Sastre-Real, María, Membrilla, Javier, Latorre, Germán, Miguel, Carlos Calle de, Luque, Sendoa Gil, Trevino-Peinado, Cristina, Quintas, Sonia, Heredia, Patricia, Echavarría-Íñiguez, Ana, Guerrero-Peral, Ángel, Sierra, Álvaro, and González-García, Nuria
- Subjects
MIGRAINE prevention ,THERAPEUTIC use of monoclonal antibodies ,RESEARCH funding ,CALCITONIN ,DESCRIPTIVE statistics ,PEPTIDES ,ANALGESICS ,DRUG efficacy ,RESEARCH ,CASE-control method ,STATISTICS ,PAIN management ,COMPARATIVE studies ,DRUG tolerance ,MIGRAINE ,EVALUATION ,CHEMICAL inhibitors ,SYMPTOMS ,OLD age - Abstract
Objective To evaluate clinical characteristics, effectiveness, and tolerability of preventive anti- calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in the elderly. Anti-CGRP mAbs have demonstrated efficacy and safety in patients with migraine although there is limited information regarding the elderly. Design We performed a multicenter case-control study of cases (patients over 65 years old) and controls (sex-matched patients under 55 years old) with migraine receiving anti-CGRP mAbs. Methods We included the demographic characteristics, effectiveness—reduction in the number of monthly headache days (MHD) and monthly migraine days (MMD), 30%, 50%, and 75% responder rates—and treatment emergent adverse events (TEAEs). The primary endpoint was the 50% response rate regarding MHD at weeks 20–24; exploratory 50% response predictors in the elderly were evaluated. Results In total, 228 patients were included: 114 cases , 114 controls-. Among cases 84.2% (96/114) were women, 79.8% (91/114) CM; mean age of cases 70.1 years old (range: 66–86); mean age of controls was 42.9 years old(range: 38–49). Cases had a higher percentage of vascular risk factors (P < .05),older age of onset (P < .001) and more reported prior preventive treatments (P < .001). Regarding effectiveness in cases, 50% response rate was achieved by 57.5% (42/73) at 20–24 weeks, with lower reduction in the MHD at 8–12 weeks (5 [7.2], 8 [9.1]; P = .001) and a higher reduction in MMD at 20–24 weeks (10.7 [9.1], 9.2 [7.7]; P = .04) compared to the control group. The percentage of TEAEs was similar in the 2 groups. Diagnosis of episodic migraine (EM) (P = .03) and lower number of MHD at baseline (P =.001) were associated with a 50% response in the elderly in univariate analysis. Conclusions Our study provides real world evidence of effectiveness and safety of anti-CGRP mAbs for migraine in patients without upper age-limit and possible predictors of anti-CGRP response in the elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Long-term outcomes of nummular headache: A series of 168 patients and 1198 patient-years of follow-up
- Author
-
García-Iglesias, Cristina, primary, González-Celestino, Ana, additional, Sierra Mencía, Álvaro, additional, González Osorio, Yésica, additional, Recio García, Andrea, additional, Martínez-Badillo, Cristina, additional, Echavarría Íñiguez, Ana, additional, Varona-Galán, Berta, additional, García-Azorín, David, additional, and Guerrero-Peral, Ángel Luis, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
- Author
-
Muñoz-Vendrell, Albert, primary, Campoy, Sergio, additional, Caronna, Edoardo, additional, Alpuente, Alicia, additional, Torres-Ferrus, Marta, additional, Nieves Castellanos, Candela, additional, Olivier, Marina, additional, Campdelacreu, Jaume, additional, Prat, Joan, additional, Camiña Muñiz, Javier, additional, Molina Martínez, Francisco José, additional, Mínguez-Olaondo, Ane, additional, Ruibal Salgado, Marta, additional, Santos Lasaosa, Sonia, additional, Navarro Pérez, María Pilar, additional, Morollón, Noemí, additional, López Bravo, Alba, additional, Cano Sánchez, Luis Miguel, additional, García-Sánchez, Sonia María, additional, García-Ull, Jésica, additional, Rubio-Flores, Laura, additional, Gonzalez-Martinez, Alicia, additional, Quintas, Sonia, additional, Echavarría Íñiguez, Ana, additional, Gil Luque, Sendoa, additional, Castro-Sánchez, María Victoria, additional, Adell Ortega, Vanesa, additional, García Alhama, Jessica, additional, Berrocal-Izquierdo, Nuria, additional, Belvís, Robert, additional, Díaz-Insa, Samuel, additional, Pozo-Rosich, Patricia, additional, and Huerta-Villanueva, Mariano, additional
- Published
- 2023
- Full Text
- View/download PDF
6. The Role of Magnetic Transcranial Stimulation in the Diagnosis and Post-Surgical Follow-Up of Cervical Spondylotic Myelopathy
- Author
-
Vázquez-Sánchez, Fernando, primary, Lloria-Gil, María del Carmen, additional, Gómez-Menéndez, Ana Isabel, additional, Isidro-Mesas, Francisco, additional, Echavarría-Íñiguez, Ana, additional, Martín-Alonso, Javier, additional, González-Bernal, Jerónimo, additional, González-Santos, Josefa, additional, Berardi, Anna, additional, Tofani, Marco, additional, Galeoto, Giovanni, additional, and García-López, Beatriz, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Treatment of Primary Nummular Headache: A Series of 183 Patients from the NUMITOR Study
- Author
-
García-Iglesias, Cristina, primary, Puledda, Francesca, additional, Echavarría-Íñiguez, Ana, additional, González-Osorio, Yesica, additional, Sierra-Mencía, Álvaro, additional, Recio-García, Andrea, additional, González-Celestino, Ana, additional, Valle-Peñacoba, Gonzalo, additional, Irimia, Pablo, additional, Guerrero-Peral, Ángel Luis, additional, and García-Azorín, David, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Treatment of Primary Nummular Headache: A Series of 183 Patients from the NUMITOR Study.
- Author
-
García-Iglesias, Cristina, Puledda, Francesca, Echavarría-Íñiguez, Ana, González-Osorio, Yesica, Sierra-Mencía, Álvaro, Recio-García, Andrea, González-Celestino, Ana, Valle-Peñacoba, Gonzalo, Irimia, Pablo, Guerrero-Peral, Ángel Luis, and García-Azorín, David
- Subjects
PRIMARY headache disorders ,TERMINATION of treatment ,BOTULINUM A toxins ,ORAL medication ,STANDARD deviations - Abstract
Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters' diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9–25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Factores de riesgo de recaída en el trastorno por uso de alcohol
- Author
-
Echavarría Íñiguez, Ana, Vázquez Bourgon, Javier, and Universidad de Cantabria
- Subjects
Risk factors ,Relapse ,Alcohol ,Recaída ,Craving ,Factores de riesgo - Abstract
El presente estudio describe la manera en que determinados factores sociodemográficos, características del consumo o distintas modalidades de tratamiento condicionan la recaída en pacientes con diagnóstico de trastorno por uso de alcohol siguiendo los criterios establecidos en el DSM-V. Para ello se emplean datos obtenidos en una población muestral de 110 pacientes incluidos en el Programa de Deshabituación Alcohólica llevado a cabo por el servicio de Psiquiatría del Hospital Universitario “Marqués de Valdecilla” entre Febrero 2001 y Febrero 2008. Se encontró, entre otros datos que: i) el craving constituye el principal factor predictor de recaída, ii) la puntuación basal obtenida en el AUDIT se correlaciona de manera significativa con el riesgo de recaída, iii) la asistencia a grupos de apoyo y un buen apoyo socio-familiar constituyen factores protectores de recaída, iv) no se encuentra significación estadística entre riesgo de recaída y factores sociodemográficos como sexo, estado civil o nivel educativo. Los resultados ponen en evidencia la importancia de la terapia combinada en el tratamiento de los trastornos por consumo de alcohol. Estudios futuros deberán ir dirigidos a implementar estrategias eficaces para combatir el craving en estos pacientes. The present study describes the way in which certain sociodemographic factors, characteristics of the consumption or different treatment modalities influence on relapse in patients with diagnosis of alcohol use disorder following the criteria established in the DSM-V. Data were obtained from a sample population of 110 patients included in the Alcohol Withdrawal Program carried out by the Psychiatric Service of the University Hospital “Marqués de Valdecilla” between February 2001 and February 2008. It was found that: i) craving is the main predictor of relapse, ii) the baseline score obtained in AUDIT correlates significantly with the risk of relapse, iii) assistance to support groups and socio-family support are protective factors for relapse, iv) there is no relationship between risk of relapse and sociodemographic factors such as sex, marital status or educational level. The results highlight the importance of psychotherapy in the treatment of alcohol-related disorders. Future studies should be directed to develop effective strategies against craving in these patients. Grado en Medicina
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.